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BRAF: Q61K/V600E) were identified in
the same DNA extract. Thus far, it is
recognized that a mutation in either
NRAS or BRAF is sufficient for activa-
tion of the Ras–Raf–MEK–ERK pathway,
with mutant RAS having a 50-fold
higher activation effect than mutant
BRAF (Davies et al., 2002). Although
we do not have any evidence that the
NRAS and BRAF mutations found in the
same DNA extract were coexisting in
the same cells, it is possible that the
L32P mutation in CDKN2A somehow
permits cellular tolerance of these dual
mutations.
In conclusion, the NRAS and BRAF
mutation rates we observed in familial
melanomas were generally lower than
those in most previous reports in
sporadic melanoma but equal to those
reported for primary melanomas of
similar thickness (Shinozaki et al.,
2004; Goel et al., 2006). Samples that
harbored INK4A L32P substitutions also
had a high frequency of coexisting
mutations in both NRAS and BRAF.
This suggests that in some instances
constitutional CDKN2A mutations
affect the occurrence of somatic
mutations in NRAS and BRAF, although
further research is needed to substanti-
ate this hypothesis.
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TO THE EDITOR
The molecular mechanisms of malig-
nant melanoma, especially epigenetic
silencing, are little understood. In parti-
cular, RAS/RAF kinases and changes in
p16 and the PTEN state have attracted
interest (see the introduction to the
Supplementary material). In our study,
epigenetic silencing of the tumor sup-
pressor genes PTEN, p16, and RASSF1A
and mutations of BRAF and NRAS
were analyzed in 619 samples of 230
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cutaneous melanomas (median tumor
thickness, 1.90 mm) from 230 patients.
All sections were reevaluated to con-
firm diagnoses and known histological
prognosis parameters. In addition, local
dermal actinic aging was scored semi-
quantitatively as previously described
(Helmbold et al., 2006). Mutations of
codon 600 of BRAF and codon 61 of
NRAS were analyzed. Promoter methy-
lation of PTEN, p16, and RASSF1A was
investigated by methylation-specific
PCR (Schagdarsurengin et al., 2006).
Mutation and methylation analyses
were confirmed in different regions of
the same tumor (mean: 2.59±0.98
Figure 1). Expression of PTEN was
studied immunohistologically in se-
lected corresponding paraffin sections.
Intercorrelations between the investi-
gated molecular and clinicopathologi-
cal features were studied. Prospective
follow-up data were used for survival
analysis. Details of all methods are
provided in the Supplementary material
(Material and Methods, Supplementary
Tables S1 and S2).
RESULTS AND DISCUSSION
In 147 of 221 (67%) melanomas, a
BRAF mutation was detected. Single-
nucleotide substitutions at position
1,799 (T4A) were detected more fre-
quently compared with two nucleotide
changes (GT4AA) at positions 1,798
and 1,799 (52 and 22%, respectively).
There was a negative correlation be-
tween the types of BRAF mutation
(P¼0.001) as well as between BRAF
(T4A) and NRAS (A4T) mutations
(P¼0.037). Ulcerated tumors exhibited
a higher frequency of BRAF mutations
compared with nonulcerated melano-
mas (75 and 58%, respectively;
P¼0.006). We found a strong negative
correlation between BRAF (T4A) mu-
tations and dermal actinic aging
(P¼0.004). (For further details see
Supplementary materials: Results, Sup-
plementary Figure S1 and Supplemen-
tary Table S3).
Methylation of RASSF1A, p16, or
PTEN was detected in 25 of 217 (12%),
46 of 213 (22%), or 120 of 200 (60%)
melanomas, respectively. There was no
correlation between the investigated
mutations and/or promoter hyper-
methylations. Positive correlations were
found between PTEN hypermethylation
and the degree of actinic aging as well
as the TANS (trunk, upper arm, neck,
and scalp) location of the tumor
(P¼0.011 and P¼0.043, respectively).
Twelve selected samples were investi-
gated for correlation between PTEN
methylation and immunohistological
PTEN expression. In the subgroup of
melanomas with an unmethylated
PTEN promoter, þ þ þ (strong), þ þ
(equivalent to endothelial cells), þ
(low), or  (no) PTEN expression was
found in 3 of 6, 2 of 6, 0 of 6, or 1 of 6
tumors, respectively. In contrast, in the
hypermethylated subgroup, the corre-
sponding frequencies were 0 of 6
(þ þ þ PTEN), 0 of 6 (þ þ PTEN), 1
of 6 (low PTEN), or 5 of 6 ( PTEN).
Further details are given in the Supple-
mentary material: Results, Supplemen-
tary Figures S2 and S3 and Supple-
mentary Table S3.
Kaplan–Meier estimations showed
that patients with tumors that are
methylated for PTEN have an increased
risk of dying compared with patients
without such methylation (P¼0.035)
(Figure 1). This was confirmed by
multivariate Cox regression analysis
(Table 1). Survival analyses showed an
additional prognostic influence of tu-
mor thickness, tumor surface diameter,
mitotic index, and age on survival, and
tumor thickness and ulceration on
recurrence-free survival (Figure 1, Table 1;
Supplementary material: Results, Sup-
plementary Figure S4, Supplementary
Tables S4 and S5).
The most interesting result of our
study is that PTEN methylation acts as
an independent prognostic parameter,
and to our knowledge this has not
previously been reported. However,
PTEN methylation as a prognostic
marker was not superior to the strongest
traditional markers (tumor thickness
and ulceration). Thus, it cannot act as
a single survival parameter for clinical
purposes. The observed frequency of
PTEN methylation was consistent with
other epigenetic data and PTEN expres-
sion analyses (Zhou et al., 2000;
Mikhail et al., 2005; Mirmohammadsa-
degh et al., 2006). Our data show a
direct relationship between PTEN hy-
permethylation and its decreased ex-
pression. The lack of expression in an
PTEN methylated
PTEN unmeth.
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Figure 1. Influence of PTEN hypermethylation on cumulative survival and methylation analysis of
PTEN promoter. (a) Overall survival stratified by PTEN methylation (n¼ 200, P¼ 0.035, confidence
interval: Supplementary Table S4). (b) DNA isolated from different regions (a, b, and c) from primary
melanomas (cases 161 and 135), in vitro methylated DNA (meth.), and unmethylated controls
(unmeth.) was treated with bisulfite and amplified by methylation-specific PCR. Methylation
(m)- and unmethylation (u)-specific PCR products of PTEN (117 and 135 bp, respectively) were
resolved on a 2% TBE gel, together with a 100-bp ladder (marker).
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unmethylated tumor could be attributed
to loss of heterozygosity of PTEN,
which is frequently observed in mela-
noma (Zhou et al., 2000). PTEN methy-
lation is lower in the melanomas of
Japanese individuals (Furuta et al.,
2004). This could be related to the
detection of a pseudogene located
on chromosome 9 (Zysman et al.,
2002). However, in silico analysis with
our utilized primers revealed only
homology with the PTEN CpG island
promoter on chromosome 10q23
(Schagdarsurengin et al., 2006). It has
been reported that decreased PTEN
expression correlated significantly
with ulceration, but not with survival
(Mikhail et al., 2005). Interestingly, the
frequency of PTEN methylation signifi-
cantly increased with the degree of
actinic aging and TANS location in our
study. This suggests an influence of
chronic UV light exposure.
The frequency of BRAF mutations in
our study (67%) and the absence of a
link between BRAF mutation and survi-
val are consistent with previous findings
(Akslen et al., 2005). In contrast to a
previously postulated influence of UV
light on BRAF mutagenesis (Besaratinia
and Pfeifer, 2008), we observed an
inverse correlation between BRAF
(T4A) mutation and dermal actinic
aging, and no correlation between
BRAF mutation and TANS tumor loca-
tion. Thus, chronic UV exposition, at
least, seems not to be a direct predictor
of BRAF (T4A) mutation. Another
difference from previous studies was
the absence of synergy between the
BRAF mutation and RASSF1A hyper-
methylation in our study. Such a
synergy was previously suggested on
the basis of only 17 cases (Reifenberger
et al., 2004).
In summary, our results show that
mutation of BRAF and methylation of
PTEN occur frequently in melanoma.
PTEN methylation correlates with tu-
mor localization or dermal actinic
aging and is an independent predictor
of impaired patient survival.
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Table 1. Multivariate Cox regression analysis of overall survival and
recurrence-free survival
Odds ratio 95% CI P-value n
Overall survival 176
Tumor diameter 2.54 1.56–4.13 0.000
Tumor thickness 2.01 1.22–3.29 0.006
PTEN methylation 1.75 1.12–2.73 0.014
Mitotic index 1.68 1.08–2.60 0.020
Age 1.54 1.00–2.39 0.052
Recurrence-free survival 223
Tumor thickness 4.29 2.43–7.58 0.000
Ulceration 1.84 1.09–3.09 0.023
CI, confidence interval; n, number of cases; P, significance level.
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